Search

Your search keyword '"Ben-David, Uri"' showing total 326 results

Search Constraints

Start Over You searched for: Author "Ben-David, Uri" Remove constraint Author: "Ben-David, Uri"
326 results on '"Ben-David, Uri"'

Search Results

3. Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage

6. Feeder-free culture of human pluripotent stem cells drives MDM4-mediated gain of chromosome 1q

8. Acute expression of human APOBEC3B in mice results in RNA editing and lethality

9. Short-term molecular consequences of chromosome mis-segregation for genome stability

10. A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling

12. The cGAS-STING, p38 MAPK, and p53 pathways link genome instability to accelerated cellular senescence in ATM-deficient murine lung fibroblasts.

13. Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells

20. Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition

21. This title is unavailable for guests, please login to see more information.

22. This title is unavailable for guests, please login to see more information.

24. Chromosome 7 to the rescue: overcoming chromosome 10 loss in gliomas

26. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling

29. CDC20 determines the sensitivity to spindle assembly checkpoint (SAC) inhibitors

30. A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancer

32. Genetic and transcriptional evolution alters cancer cell line drug response

33. Supplementary figure 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting

34. Data from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting

35. Supplementary figure 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting

36. Supplementary table 1 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting

37. Supplementary table 2 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting

38. Supplementary table 3 from Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting

39. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting

43. Supplementary Figures S6 - S10 from Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting

44. Supplementary Table S1 from Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting

45. Supplementary Figure Legends from Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting

46. Data from Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting

47. Supplementary Methods from Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting

50. Supplementary Table 1 from Landscape of Genomic Alterations in Pituitary Adenomas

Catalog

Books, media, physical & digital resources